Consolidated revenue of 8.28 billion KRW (up 48% YoY from 5.59 billion), consolidated net profit of 1.45 billion KRW, turning from a loss of 500 million KRW in the same period last year
Separate revenue of 8.28 billion KRW, net profit of 1.54 billion KRW (vs loss of 555 million KRW in prior year)
Cash and cash equivalents at 2.83 billion KRW (up from 1.66 billion at year-end 2025), net debt ratio improved to 43% (from 45%)
Credit rating BBB- (downgraded from BBB0 in April 2025) - minor negative but still investment grade
Holding 234,089 treasury shares (acquired in 2023), no further buyback or cancellation plans
Shareholder return policy: target 30-40% payout ratio of separate net profit over next 5 years, considering treasury share acquisition/cancellation
Order backlog of 23.6 billion KRW (including university ERP projects at Korea Univ., Jeonbuk Univ., Wonkwang Univ., etc.)
Subsidiary CyberMDCare (US healthcare) reported net loss of 330 million KRW this quarter (loss reduced from 1.58 billion last year)
R&D expenditure of 204 million KRW (down from 1.006 billion prior year, 2.46% of revenue)